Modified risk associations of lipoproteins and apolipoproteins by chronic low-grade inflammation

References

• Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardio-metabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabet Endocrinol. 2014;2:634–647.
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Tsunoda F, Diffenderfer M, et al. The measurement of lipids, lipoproteins, apolipoproteins, fatty acids, and sterols, and next generation sequencing for the diagnosis and treatment of lipid disorders. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2016.
   Google Scholar
• Ellis KL, Hooper AJ, Burnett JR, et al. Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nat Rev Endocrinol. 2016;12:467–484.
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Hergenç G, et al. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension, diabetes, independent of markers of central obesity and inflammation. Int J Obes. 2007;31:1119–1125.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853.
   PubMed Web of Science ®Google Scholar
• Dubé JB, Boffa MB, Hegele RA, et al. Lipoprotein (a): more interesting than ever after 50 years. Curr Opin Lipidol. 2012;23:133–140.
   PubMed Web of Science ®Google Scholar
• Chretien JP, Coresh J, Berthier-Schaad Y, et al. Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein (a) level elevation in African Americans compared with European Americans. J Med Genet. 2006;43:917–923.
   PubMed Web of Science ®Google Scholar
• Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein (a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125:241–249.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–2339.
   PubMed Web of Science ®Google Scholar
• Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein (a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55:2160–2167.
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–2528.
   PubMed Web of Science ®Google Scholar
• Guan W, Cao J, Steffen BT, et al. Race is a key variable in assigning lipoprotein (a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35::996–1001.
   PubMed Web of Science ®Google Scholar
• Forbang NI, Criqui MH, Allison MA, et al. Sex and ethnic differences in the associations between lipoprotein (a) and peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis. J Vasc Surg. 2016;63:453–458.
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57:526–537.
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–423.
   PubMed Web of Science ®Google Scholar
• Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein (a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64:851–860.
   PubMed Web of Science ®Google Scholar
• Vonbank A, Saely CH, Rein P, et al. Lipoprotein (a), the metabolic syndrome and vascular risk in angiographied coronary patients. J Clin Endocrinol Metab. 2016;101:3199–3203.
   PubMed Web of Science ®Google Scholar
• Zewinger S, Kleber ME, Tragante V, et al. Relations between lipoprotein (a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol. 2017;5:534–543.
   PubMed Web of Science ®Google Scholar
• Leibundgut G, Arai K, Orsoni A, et al. Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol. 2012;59:1426–1437.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp (a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46–57.
   PubMed Web of Science ®Google Scholar
• Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536–1544.
   PubMed Web of Science ®Google Scholar
• Cook NR, Paynter NP, Manson JE, et al. Clinical utility of lipoprotein-associated phospholipase A2 for cardiovascular risk prediction in a multiethnic cohort of women. Clin Chem. 2012;58:1352–1363.
   PubMed Web of Science ®Google Scholar
• Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein (a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort study). Am J Cardiol. 1995;76:928–932.
   PubMed Web of Science ®Google Scholar
• Bozbas H, Yildirir A, Atar I, et al. Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification. J Heart Valve Dis. 2007;16:387–393.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein (a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470–477.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein (a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386:1472–1483.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Viney N, Crooke R, et al. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57:340–351.
   PubMed Web of Science ®Google Scholar
• Romagnuolo R, Scipione CA, Boffa MB, et al. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low-density lipoprotein receptor. J Biol Chem. 2015;290:11649–11662.
   PubMed Web of Science ®Google Scholar
• Murphy AJ. High density lipoprotein: assembly, structure, cargo, and functions. ISRN Physiology. 2013;1–20. DOI:10.1155/2013/186365
   Google Scholar
• The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease: individual data analysis of 302,430 participants from 68 prospective studies. JAMA. 2009;302:1993–2000.
   PubMed Web of Science ®Google Scholar
• Expert panel on detection, Evaluation and treatment of high blood cholesterol in adults.Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Fizelova M, Miilunpohja M, Kangas AJ, et al. Associations of multiple lipoprotein and apolipoprotein measures with worsening of glycemia and incident type 2 diabetes in 6607 non-diabetic Finnish men. Atherosclerosis. 2015;240:272–277.
   PubMed Web of Science ®Google Scholar
• Zheng C, Aikawa M. High-density lipoproteins. J Am Coll Cardiol. 2012;60:2380–2383.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Zheng C, Cohn JS. Complexities of plasma apolipoprotein C-III metabolism. J Lipid Res. 2011;52:1067–1070.
   PubMed Web of Science ®Google Scholar
• Holzer M, Birner-Grünberger A, Stojakovic T, et al. Uremia alters HDL composition and function. J Am Soc Nephrol. 2011;22:1631–1641.
   PubMed Web of Science ®Google Scholar
• Wyler von Ballmoos MC, Haring B, Sacks FM. The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis. Nat Rev Cardiol. 2016;13:48–60.
   PubMedGoogle Scholar
• Onat A, Hergenç G, Sansoy V, et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of adverse risk profile in both genders. Atherosclerosis. 2003;168:81–89.
   PubMed Web of Science ®Google Scholar
• Onat A, Hergenç G, Ayhan E, et al. Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor among Turks. Diabet Med. 2009; 26;981–88.
   PubMed Web of Science ®Google Scholar
• Pechlaner R, Tsimikas S, Yin X, et al. Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III. J Am Coll Cardiol. 2017;69:789–800.
   PubMed Web of Science ®Google Scholar
• Rocha NA, East C, Zhang J, et al. ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen. Curr Atheroscler Rep. 2017;19:62.
   PubMed Web of Science ®Google Scholar
• Vuilleumier N, Charbonney E, Fontao L, et al. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clin Sci. 2008;115:25–33.
   PubMed Web of Science ®Google Scholar
• Vuilleumier N, Bas S, Pagano S, et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2010;62:2640–2650.
   PubMedGoogle Scholar
• Rubini Gimenez M, Pagano S, Virzi J, et al. Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A-1 and antiphosphorylcholine in acute non-ST elevation myocardial infarction. Eur J Clin Invest. 2015;45:369–379.
   PubMed Web of Science ®Google Scholar
• Croca S, Bassett P, Chambers S, et al. IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. Arthritis Res Ther. 2015;17:26.
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Orekhov AN, Bobryshev YV. ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease. Lab Invest. 2016;96:708–718.
   PubMed Web of Science ®Google Scholar
• Di Angelantonio E, Gao P, Pennells L, et al. Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. J Am Med Assoc. 2012;307:2499–2506.
   PubMedGoogle Scholar
• Onat A, Hergenç G, Can G, et al. Dual activity of serum lipoprotein-associated phospholipase A2 yielding positive and inverse associations with cardiometabolic risk. Clin Chem Lab Med. 2011;49:1349–1357.
   PubMed Web of Science ®Google Scholar
• Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016;67:2118–2130.
   PubMed Web of Science ®Google Scholar
• Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr Cardiol. 2002;11:101–117.
   PubMedGoogle Scholar
• Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350:1119–1123.
   PubMed Web of Science ®Google Scholar
• De Ruijter W, Westendorp RGJ, Assendelft WJJ, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ. 2009;338:a3083.
   PubMed Web of Science ®Google Scholar
• Onat A, Hergenç G, Küçükdurmaz Z, et al. Serum folate is associated with coronary heart disease independently of homocysteine in Turkish men. Clin Nutr. 2008;27:732–739.
   PubMed Web of Science ®Google Scholar
• Van Der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51:634–642.
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Ayhan E, et al. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism. 2009;58:1393–1399.
   PubMed Web of Science ®Google Scholar
• Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study. Lancet. 2012;380:572–580.
   PubMed Web of Science ®Google Scholar
• Ko DT, Alter DA, Guo H, et al. High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study. J Am Coll Cardiol. 2016;68:2073–2083.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Kei A, Elisaf MS. Anacetrapib, a new CETP inhibitor: the new tool for the management of dyslipidemias? Diseases. 2017;5:21.
   Google Scholar
• Eyvazian VA, Frishman WH. Evacetrapib: another CETP inhibitor for dyslipidemia with no clinical benefit. Cardiol Rev. 2017;25:43–52.
   PubMed Web of Science ®Google Scholar
• Namiri-Kalantari R, Gao F, Chattopadhyay A, et al. The dual nature of HDL: anti-inflammatory and pro-inflammatory. Biofactors. 2015;41(3):153–159.
   PubMed Web of Science ®Google Scholar
• Chang CT, Yang CY, Tsai FJ, et al. Mass spectrometry-based proteomic study makes high-density lipoprotein a biomarker for atherosclerotic vascular disease. Biomed Res Int. 2015;164846:1–13.
   Google Scholar
• Qi Y, Fan J, Liu J, et al. Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. J Am Coll Cardiol. 2015;65:355–363.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Brewer HB Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. J Lipid Res. 2016;57(3):340–351.
   PubMedGoogle Scholar
• Onat A, Hergenç G, Bulur S, et al. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol. 2010;142:72–79.
   PubMed Web of Science ®Google Scholar
• Corsetti JP, Bakker SJ, Sparks CE, et al. Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease in women with high levels of HDL cholesterol and C-reactive protein. PLoS One. 2012;7(6):e39110.
   PubMed Web of Science ®Google Scholar
• Kontush A, Chapman MJ. Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep. 2008;8:51–59.
   PubMed Web of Science ®Google Scholar
• Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45:993–1007.
   PubMed Web of Science ®Google Scholar
• Ansell BJ, Navab M, Hama S, et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–2756.
   PubMed Web of Science ®Google Scholar
• Onat A, Örnek E, Çiçek G, et al. Increased apolipoprotein A-I levels mediate the development of prehypertension. Anadolu Kardiyol Derg. 2013;13:306–314.
   PubMedGoogle Scholar
• Onat A, Hergenç G, Ayhan E, et al. Impaired anti-inflammatory function of apolipoprotein A-II concentrations predict metabolic syndrome and diabetes at 4 years follow-up in elderly Turks. Clin Chem Lab Med. 2009;47:1389–1394.
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Örnek E, et al. High serum apolipoprotein E determines hypertriglyceridemic dyslipidemias, coronary disease and apo A-I dysfunctionality. Lipids. 2013;48:51–61.
   PubMed Web of Science ®Google Scholar
• Mora S, Kamstrup PR, Rifai N, et al. Lipoprotein(a) and risk of type-2 diabetes. Clin Chem. 2010;56:1252–1260.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomization study. Lancet Diabetes Endocrinol. 2013;1:220–227.
   PubMed Web of Science ®Google Scholar
• Ye Z, Haycock PC, Gurdasani D, et al. The association between circulating lipoprotein(a) and type 2 diabetes. Diabetes. 2014;63:332–342.
   PubMed Web of Science ®Google Scholar
• Paige E, Masconi KL, Tsimikas S, et al. Lipoprotein (a) and incident type 2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017;16:38.
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Ornek E, et al. Abdominal obesity with hypertriglyceridemia, lipoprotein(a) and apolipoprotein A-I, determine marked cardiometabolic risk. Eur J Clin Invest. 2013;43:1129–1139.
   PubMed Web of Science ®Google Scholar
• Onat A, Çoban N, Can G, et al. Low ‘quotient’ Lp(a) concentration mediates autoimmune activation and independently predicts cardiometabolic risk. Exp Clin Endocr Diabetes. 2015;123:11–18.
   PubMed Web of Science ®Google Scholar
• Yu Q, Chen Y, Xu CB. Statins and new-onset diabetes mellitus: LDL receptor may provide a key link. Front Pharmacol. 2017;8:372.
   PubMed Web of Science ®Google Scholar
• Sawabe M, Tanaka N, Mieno MN, et al. Low lipoprotein (a) concentration is associated with cancer and all-cause deaths: a population-based cohort study (the JMS Cohort Study). PLoS One. 2012;7:e31954.
   PubMed Web of Science ®Google Scholar
• Motta M, Giugno I, Ruello P, et al. Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. Minerva Med. 2001;92:301–315.
   PubMedGoogle Scholar
• Onat A, Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des. 2014;20:575–584.
   PubMed Web of Science ®Google Scholar
• Onat A, Ademoglu E, Can G, et al. Lower circulating migration inhibitory factor protein is associated with metabolic syndrome and diabetes. Biomark Med. 2017;11:557–568.
   PubMed Web of Science ®Google Scholar
• Bellamy L, Casas J, Hingorani A, et al. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974,86.
   Google Scholar
• McDonald S, Malinowski A, Zhou Q, et al. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analysis. Am Heart J. 2008;156:918–930.
   PubMed Web of Science ®Google Scholar
• Todros T, Bontempo S, Piccoli E, et al. Increased levels of macrophage migration inhibitory factor (MIF) in preeclampsia. Eur Obst Gynecol Reprod Biol. 2005;123:162–166.
   PubMed Web of Science ®Google Scholar
• Cardaropoli S, Letta F, Romagnoli R, et al. Lower macrophage migration inhibitory factor concentrations in maternal serum before pre-eclampsia onset. J Interferon Cytokine Res. 2014;34:537–542.
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Çoban N, et al. Lipoprotein(a) level and MIF gene variant predict incident metabolic syndrome and mortality. J Investig Med. 2016;64:392–399.
   PubMed Web of Science ®Google Scholar
• Kon V, Yang H, Fazio S. Residual cardiovascular risk in chronic kidney disease: role of high-density lipoprotein. Arch Med Res. 2015;46(5):379–391.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010;69:310–314.
   Web of Science ®Google Scholar
• Mora S, Akinkuolie AO, Sandhu RK, et al. Paradoxical association of lipoprotein measures with incident atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7:612–619.
   PubMed Web of Science ®Google Scholar
• Johnson LSB, Juhlin T, Engström G, et al. Low fasting plasma insulin is associated with atrial fibrillation in men from a cohort study – the Malmö Preventive Project. BMC Cardiovasc Disord. 2014;14:107.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis. 1996;27:1–25.
   PubMed Web of Science ®Google Scholar
• Polachek A, Touma Z, Anderson M, et al. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthrit Care Res. 2016;69(1):67–74.
   Web of Science ®Google Scholar
• De Seny D, Cobraiville G, Charlier E, et al. Apolipoprotein-AI as a damage-associated molecular patterns protein in osteoarthritis: ex vivo and in vitro proinflammatory properties. PLoS One. 2015;10:e0122904.
   PubMed Web of Science ®Google Scholar
• Wibetoe G, Ikdahl E, Rollefstad S, et al. Cardiovascular disease risk profiles in inflammatory joint disease entities. Arthit Res Ther. 2017;19:153.
   PubMed Web of Science ®Google Scholar
• Lotta LA, Sharp SJ, Burgess S, et al. Association between LDL-cholesterol lowering genetic variants and risk of type 2 diabetes. JAMA. 2016;316:1383–1391.
   PubMed Web of Science ®Google Scholar